

# ESMO PRECEPTORSHIP PROGRAMME

## LUNG CANCER AND OTHER THORACIC MALIGNANCIES

New standards of care and future perspectives

**Paris, France**  
**17-18 November 2022**

**CO-CHAIRS:** Fabrice Barlesi, France  
 Solange Peters, Switzerland  
 David Planchard, France

**SPEAKERS:** Benjamin Besse, France  
 Corinne Faivre-Finn, United Kingdom  
 Marina Garassino, United States  
 Lizza Hendriks, Netherlands  
 Keith M. Kerr, United Kingdom  
 Cécile Le Pechoux, France  
 Tony S.K. Mok, Hong Kong  
 Luis Paz-Ares, Spain  
 Sanjay Popat, United Kingdom

### LEARNING OBJECTIVES

- To learn about best clinical practice in the management of NSCLC in early, locally advanced and metastatic stages
- To learn about the management of patients with actionable driver alterations and novel targeted agents for advanced NSCLC
- To understand the role of immune checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about the systemic treatment of mesothelioma, SCLC and thymoma

### Thursday, 17 November 2022

09:00-09:10 10'	Welcome and introduction	David Planchard, FR Solange Peters, CH
09:10-11:10 120'	<b>SESSION 1</b> Multimodality treatment in early stage	Co-Chairs: Luis Paz-Ares, ES Fabrice Barlesi, FR
25'	Adjuvant RT for completely resected early stage NSCLC and treatment of oligometastatic disease NSCLC	Cécile Le Pechoux, FR
5'	Q&A	Faculty
25'	IO or targeted therapies in the peri-operative setting for NSCLC	Solange Peters, CH
5'	Q&A	Faculty
25'	Stereotactic ablative RT for early stage NSCLC	Corinne Faivre-Finn, UK
5'	Q&A	Faculty
30'	Participants clinical discussion (2x15')	Faculty
11:10-11:40	Coffee break	

<b>11:40-13:25 105'</b>	<b>SESSION 2 Immuno-oncology treatment paradigms</b>	<b>Co-Chairs: David Planchard, FR Lizza Hendriks, NL</b>
25'	The treatment paradigm for unresectable stage III NSCLC	Fabrice Barlesi, FR
5'	Q&A	Faculty
25'	Treatment of metastatic NSCLC with absent PD-L1 expression and without oncogene addiction	Luis Paz-Ares, ES
5'	Q&A	Faculty
25'	Treatment of metastatic NSCLC with PD-L1 expression and without oncogene addiction	Solange Peters, CH
5'	Q&A	Faculty
15'	Participants clinical discussion (1x15')	Faculty
<b>13:25-14:25</b>	<b>Lunch</b>	
<b>14:25-16:10 105'</b>	<b>SESSION 3 Challenges and novel therapies in clinical oncology</b>	<b>Co-Chairs: Tony S.K. Mok, HK Keith M. Kerr, UK</b>
25'	Second-line treatment for advanced NSCLC	Lizza Hendriks, NL
5'	Q&A	Faculty
25'	Prognostic and predictive biomarkers for IO	Solange Peters, CH
5'	Q&A	Faculty
25'	Antibody drug conjugates and Bi-specific Ab	David Planchard, FR
5'	Q&A	Faculty
15'	Participants clinical discussion (1x15')	Faculty
<b>16:10-16:40</b>	<b>Coffee break</b>	
<b>16:40-18:40 120'</b>	<b>SESSION 4 Hitting the target in 2022</b>	<b>Co-Chairs: Benjamin Besse, FR Lizza Hendriks, NL</b>
25'	Sequence for biomarker testing in advanced NSCLC (IHC, PCR, NGS and more)	Keith M. Kerr, UK
5'	Q&A	Faculty
25'	New treatment options for EGFRmut NSCLC	Tony S.K. Mok, HK
5'	Q&A	Faculty
25'	The patient with an EGFR or HER2 Exon 20 insertion	Marina Garassino, US
5'	Q&A	Faculty
30'	Participants clinical discussion (2x15')	Faculty
<b>19:30</b>	<b>Dinner</b>	

## Friday, 18 November 2022

<b>09:00-11:00</b> <b>120'</b>	<b>SESSION 5</b> <b>Hitting the target in 2021</b>	<b>Co-Chairs: Sanjay Popat, UK</b> <b>David Planchard, FR</b>
25'	New treatment options for non-EGFR/HER2 mutations	Fabrice Barlesi, FR
5'	Q&A	Faculty
25'	Gene fusion targets	Benjamin Besse, FR
5'	Q&A	Faculty
25'	ctDNA in the management of NSCLC patients	Marina Garassino, US
5'	Q&A	Faculty
30'	Participants clinical discussion (2x15')	Faculty
<b>11:00-11:30</b>	<b>Coffee break</b>	
<b>11:30-13:15</b> <b>105'</b>	<b>SESSION 6</b> <b>Treatment paradigms in more rare situations</b>	<b>Co-Chairs: Fabrice Barlesi, FR</b> <b>Marina Garassino, US</b>
25'	The evolving treatment landscape for mesothelioma	Sanjay Popat, UK
5'	Q&A	Faculty
25'	Thymic malignancies: New treatments	Benjamin Besse, FR
5'	Q&A	Faculty
25'	What's next in the management of SCLC?	David Planchard, FR
5'	Q&A	Faculty
15'	Participants clinical discussion (1x15')	Faculty
<b>13:15-13:25</b> <b>10'</b>	<b>Conclusion and farewell</b>	<b>Fabrice Barlesi, FR</b> <b>David Planchard, FR</b>
<b>13:25-14:25</b>	<b>Lunch</b>	

Note: Each 15 min slot for clinical case discussion includes 7' case presentation and 8' Q&A / interactive panel discussion